1. Home
  2. RCKT vs AKRO Comparison

RCKT vs AKRO Comparison

Compare RCKT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCKT
  • AKRO
  • Stock Information
  • Founded
  • RCKT 1999
  • AKRO 2017
  • Country
  • RCKT United States
  • AKRO United States
  • Employees
  • RCKT N/A
  • AKRO N/A
  • Industry
  • RCKT Biotechnology: Pharmaceutical Preparations
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • RCKT Health Care
  • AKRO Health Care
  • Exchange
  • RCKT Nasdaq
  • AKRO Nasdaq
  • Market Cap
  • RCKT 1.9B
  • AKRO 2.1B
  • IPO Year
  • RCKT N/A
  • AKRO 2019
  • Fundamental
  • Price
  • RCKT $16.98
  • AKRO $32.33
  • Analyst Decision
  • RCKT Strong Buy
  • AKRO Strong Buy
  • Analyst Count
  • RCKT 9
  • AKRO 7
  • Target Price
  • RCKT $53.22
  • AKRO $43.20
  • AVG Volume (30 Days)
  • RCKT 641.8K
  • AKRO 505.3K
  • Earning Date
  • RCKT 11-12-2024
  • AKRO 11-11-2024
  • Dividend Yield
  • RCKT N/A
  • AKRO N/A
  • EPS Growth
  • RCKT N/A
  • AKRO N/A
  • EPS
  • RCKT N/A
  • AKRO N/A
  • Revenue
  • RCKT N/A
  • AKRO N/A
  • Revenue This Year
  • RCKT N/A
  • AKRO N/A
  • Revenue Next Year
  • RCKT $382.35
  • AKRO N/A
  • P/E Ratio
  • RCKT N/A
  • AKRO N/A
  • Revenue Growth
  • RCKT N/A
  • AKRO N/A
  • 52 Week Low
  • RCKT $15.98
  • AKRO $13.39
  • 52 Week High
  • RCKT $32.53
  • AKRO $37.00
  • Technical
  • Relative Strength Index (RSI)
  • RCKT 44.74
  • AKRO 64.31
  • Support Level
  • RCKT $16.48
  • AKRO $30.13
  • Resistance Level
  • RCKT $17.75
  • AKRO $32.70
  • Average True Range (ATR)
  • RCKT 0.70
  • AKRO 1.42
  • MACD
  • RCKT 0.00
  • AKRO 0.11
  • Stochastic Oscillator
  • RCKT 20.75
  • AKRO 86.40

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: